SEARCH

SEARCH BY CITATION

References

  • 1
    Pozniak AL, Gallant JE, Dejesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz vs. fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes – a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535540.
  • 2
    Izzedine H, Hulot JS, Vittecoq D et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743746.
  • 3
    Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 41: 570571.
  • 4
    Winston A, Amin J, Mallon PWG et al, Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7: 105111.
  • 5
    Van Rompay KK, Brignolo LL, Meyer DJ et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48: 14691487.
  • 6
    Peyriere H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269273.
  • 7
    Izzedine H, Isnard-Bagnis C, Hulot JS et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 10741076.
  • 8
    Parsonage MJ, Wilkins EGL, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341346.
  • 9
    Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A.
  • 10
    Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 15431546.
  • 11
    Lane C, Brown M, Dunsmuir W, Kelly J, Mangos G. Can spot urine protein/creatinine ratio replace 24hr urine protein in usual clinical nephrology? Nephrology (Carlton) 2006; 11: 245249.
  • 12
    Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998; 316: 504509.
  • 13
    Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 9395.
  • 14
    Gallant JE, Staszewski S, Pozniak AL et al. & 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292: 191201.
  • 15
    Brown TT, Quarqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 21652174.
  • 16
    Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006; 52: 335338.
  • 17
    Norden AG, Lapsley M, Lee PJ et al. Glomerular protein sieving and implications for renal failure in Fanconi Syndrome. Kidney Int 2001; 60: 18851892.
  • 18
    Kabanda A, Vandercam B, Lauwerys R, Van Ypersele de Strihou C. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis 1996; 27: 803808.
  • 19
    Biesecker G, Karimi S, Desjardins J et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 2003; 58: 217225.
  • 20
    Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716723.
  • 21
    Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278283.
  • 22
    Ray AS, Cihlar T, Robinson KL et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 32973304.
  • 23
    Cihlar T, Ray AS, Laflamme G et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12: 267272.